Biomarin Pharmaceutical Inc

BMRNNASDAQ · USD
56.03USD-0.09 (-0.16%)
477

Biomarin Pharmaceutical Inc (BMRN) Historical Volatility

BMRN's 30 day historical volatility is 29.11%, in the 56th percentile of readings over the past year. This is an average percentile, meaning Biomarin Pharmaceutical Inc shares have moved roughly in line with their typical range. BMRN's 30 day implied volatility sits at 38.55%, with an IV Rank of 31.35%, leaving IV 9.44 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 5, 2026.

Read more

Tracking BMRN historical volatility helps you see how much Biomarin Pharmaceutical Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, BMRN's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor BMRN 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. BMRN's 30 day historical volatility, or BMRN HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing BMRN's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.

Historical Volatility

HV Percentile
56thHV Percentile
Moderate

Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.

Historical Volatility (30d)29.11%

HV Percentile56th

Implied Volatility (30d)38.55%

IV Rank31.35%

IV Minus HV+9.44%

As of Nov 5, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 5, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 5, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $2,243. Ending soon.See the Early Bird Black Friday deal →